{"id":11904,"date":"2023-11-08T21:36:00","date_gmt":"2023-11-08T13:36:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11904"},"modified":"2024-11-09T21:47:26","modified_gmt":"2024-11-09T13:47:26","slug":"senti-biosciences-and-celest-therapeutics-partner-on-car-nk-cell-therapy-clinical-trial-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11904","title":{"rendered":"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China"},"content":{"rendered":"\n

Senti Biosciences Inc., (NASDAQ: SNTI<\/a>), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti\u2019s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will provide technical support while Celest oversees manufacturing, clinical development, and operations.<\/p>\n\n\n\n

Expanding Clinical Development and Commercial Rights<\/strong>
The collaboration may extend to the Greater China territory, including Hong Kong, Macau, and Taiwan, with Celest holding commercial rights within that expanded territory. The deal terms include potential milestone payments of up to USD 156 million from Celest to Senti, plus tiered royalties on future sales. The announcement led to a 78% surge in Senti’s stock value.<\/p>\n\n\n\n

Pilot Study and Patient Recruitment<\/strong>
Celest aims to recruit the first patient for the mainland China pilot study in the first half of 2024, targeting nine patients with advanced glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC) across two dose cohorts. The study’s objectives are to assess safety and establish dosage for SENTI-301A. GPC3 antigen is highly expressed in 70%-90% of HCC tumors, making it a significant target, while it has little or no expression in normal tissue.<\/p>\n\n\n\n

SENTI-301A’s Synthetic Biology Platform and Immuno-stimulatory Payload<\/strong>
SENTI-301A is developed on Senti\u2019s proprietary synthetic biology platform, Gene Circuits, and includes calibrated release interleukin-15 (crIL-15), an immuno-stimulatory payload designed to stimulate surrounding immune cells and promote CAR-NK cell expansion, persistence, and tumor killing. Having completed preclinical testing, SENTI-301A has demonstrated robust in vitro and in vivo killing of relevant tumor cells.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[30,16,21,1990,77,20,1989,1988],"class_list":["post-11904","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-cancer","tag-car-t","tag-celest-therapeutics","tag-cell-therapy","tag-finance","tag-nasdaq-snti","tag-senti-biosciences"],"yoast_head":"\nSenti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti\u2019s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will provide technical support while Celest oversees manufacturing, clinical development, and operations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11904\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11904\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-08T13:36:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-09T13:47:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11904#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11904\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China\",\"datePublished\":\"2023-11-08T13:36:00+00:00\",\"dateModified\":\"2024-11-09T13:47:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11904\"},\"wordCount\":287,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Cancer\",\"CAR-T\",\"Celest Therapeutics\",\"Cell-therapy\",\"Finance\",\"NASDAQ: SNTI\",\"Senti Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11904#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11904\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11904\",\"name\":\"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-08T13:36:00+00:00\",\"dateModified\":\"2024-11-09T13:47:26+00:00\",\"description\":\"Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti\u2019s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will provide technical support while Celest oversees manufacturing, clinical development, and operations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11904#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11904\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11904#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China - Insight, China's Pharmaceutical Industry","description":"Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti\u2019s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will provide technical support while Celest oversees manufacturing, clinical development, and operations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11904","og_locale":"en_US","og_type":"article","og_title":"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11904","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-08T13:36:00+00:00","article_modified_time":"2024-11-09T13:47:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11904#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11904"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China","datePublished":"2023-11-08T13:36:00+00:00","dateModified":"2024-11-09T13:47:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11904"},"wordCount":287,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Cancer","CAR-T","Celest Therapeutics","Cell-therapy","Finance","NASDAQ: SNTI","Senti Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11904#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11904","url":"https:\/\/flcube.com\/?p=11904","name":"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-08T13:36:00+00:00","dateModified":"2024-11-09T13:47:26+00:00","description":"Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti\u2019s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will provide technical support while Celest oversees manufacturing, clinical development, and operations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11904#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11904"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11904#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11904"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11904\/revisions"}],"predecessor-version":[{"id":11906,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11904\/revisions\/11906"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}